ANNUAL SAFETY REPORT UHKT-CAR123-01 Period: 5. 9.2024 – 4. 9.2025
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F25%3A00143491" target="_blank" >RIV/00216224:14110/25:00143491 - isvavai.cz</a>
Result on the web
<a href="https://ctis.eu/search/trial/2022-503165-30-00.html" target="_blank" >https://ctis.eu/search/trial/2022-503165-30-00.html</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
ANNUAL SAFETY REPORT UHKT-CAR123-01 Period: 5. 9.2024 – 4. 9.2025
Original language description
The first annual report summarizes the safety data received by the study sponsor from September 5, 2024 to September 4, 2025. The clinical study is a monocentric study taking place in the Czech Republic. Patients with relapsed and refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-grade myelodysplastic syndromes (MDS) and, blastic plasmacytoid dendritic cell neoplasm (BPDCN) have poor outcome and novel strategies are needed to treat such patients. CD123 antigen is expressed on high proportion of these tumors. The study focuses on the safety and efficacy of autologous CART123 lymphocytes in patients with relapsed or refractory CD123 positive hematological malignancies.
Czech name
—
Czech description
—
Classification
Type
V<sub>souhrn</sub> - Summary research report
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
—
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Number of pages
40
Place of publication
Praha
Publisher/client name
ÚHKT
Version
—